A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Published on Mar 1, 2014in BJUI4.806
· DOI :10.1111/BJU.12623
Maria Pearse9
Estimated H-index: 9
(Auckland City Hospital),
Carol Fraser-Browne7
Estimated H-index: 7
(Auckland City Hospital)
+ 17 AuthorsAndrew Kneebone29
Estimated H-index: 29
Objectives To test the hypothesis that observation with early salvage radiotherapy (SRT) is not inferior to ‘standard’ treatment with adjuvant RT (ART) with respect to biochemical failure in patients with pT3 disease and/or positive surgical margins (SMs) after radical prostatectomy (RP). To compare the following secondary endpoints between the two arms: patient-reported outcomes, adverse events, biochemical failure-free survival, overall survival, disease-specific survival, time to distant failure, time to local failure, cost utility analysis, quality adjusted life years and time to androgen deprivation. Patients and Methods The Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial is a phase III multicentre randomised controlled trial led by the Trans Tasman Radiation Oncology Group (TROG), in collaboration with the Urological Society of Australia and New Zealand (USANZ), and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). In all, 470 patients are planned to be randomised 1:1 to either ART commenced at ≤4 months of RP (standard of care) or close observation with early SRT triggered by a PSA level of >0.20 ng/mL (experimental arm). Eligible patients have had a RP for adenocarcinoma of the prostate with at least one of the following risk factors: positive SMs ± extraprostatic extension ± seminal vesicle involvement. The postoperative PSA level must be ≤0.10 ng/mL. Rigorous investigator credentialing and a quality assurance programme are designed to promote consistent RT delivery among patients. Results Trial is currently underway, with 258 patients randomised as of 31 October 2013. International collaborations have developed, including a planned meta-analysis to be undertaken with the UK Medical Research Council/National Cancer Institute of Canada Clinical Trials Group RADICALS (Radiotherapy and Androgen Deprivation In Combination with Local Surgery) trial and an innovative psycho-oncology sub-study to investigate a patient decision aid resource. Conclusion On the current evidence available, it remains unclear if ART is equivalent or superior to observation with early SRT.
📖 Papers frequently viewed together
997 Citations
201260.39The Lancet
19 Authors (Michel Bolla, ..., Laurence Collette)
605 Citations
306 Citations
#1Michel BollaH-Index: 56
#2Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
Last. Laurence Collette (European Organisation for Research and Treatment of Cancer)H-Index: 86
view all 19 authors...
Summary Background We report the long-term results of a trial of immediate postoperative irradiation versus a wait-and-see policy in patients with prostate cancer extending beyond the prostate, to confirm whether previously reported progression-free survival was sustained. Methods This randomised, phase 3, controlled trial recruited patients aged 75 years or younger with untreated cT0–3 prostate cancer (WHO performance status 0 or 1) from 37 institutions across Europe. Eligible patients were ran...
605 CitationsSource
#1Alberto BrigantiH-Index: 96
#2Thomas WiegelH-Index: 50
Last. Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
view all 14 authors...
Background: Previous randomised trials demonstrated that adjuvant radiation therapy (aRT) improves cancer control in patients with pT3 prostate cancer (PCa). However, there is currently no evidence supporting early salvage radiation therapy (eSRT) as equivalent to aRT in improving freedom from biochemical recurrence (BCR) after radical prostatectomy (RP). Objective: To evaluate BCR-free survival for aRT versus observation followed by eSRT in cases of relapse in patients undergoing RP for pT3pN0,...
142 CitationsSource
#1Puma Sundaresan (RPA: Royal Prince Alfred Hospital)H-Index: 10
#2Sandra Turner (Westmead Hospital)H-Index: 30
Last. Phyllis Butow (USYD: University of Sydney)H-Index: 108
view all 5 authors...
Abstract Randomised controlled trials (RCTs) can be hampered by poor patient accrual and retention. Decision aids (DAs) containing simple, evidence-based information, may assist patients with decision-making regarding trial participation. The current DA was of use for 95% of participants. Further evaluation of the DA in a RCT is currently underway.
22 CitationsSource
#1Andrew J. Stephenson (Cleveland Clinic)H-Index: 57
#2Scott E. Eggener (U of C: University of Chicago)H-Index: 71
Last. Peter T. Scardino (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 159
view all 9 authors...
Background: Positive surgical margins (PSMs) in radical prostatectomy (RP) specimens are a frequent indication for adjuvant radiotherapy and are used as a measure of surgical quality. However, the association between PSMs and prostate cancer–specific mortality (CSM) is poorly defined. Objective: Analyze the association of PSMs with CSM, adjusting for fixed and timedependent parameters. Design, setting, and participants: Fine and Gray competing risk regression analysis was used to model the clini...
60 CitationsSource
#1Tom Budiharto (Katholieke Universiteit Leuven)H-Index: 14
#2Christiaan Perneel (Royal Military Academy)H-Index: 14
Last. Hendrik Van Poppel (Katholieke Universiteit Leuven)H-Index: 82
view all 11 authors...
In men with adverse pathology at the time of radical prostatectomy (RP), the most appropriate timing to administer radiotherapy (RT) remains a subject for debate. To determine whether salvage radiotherapy (SRT) upon early prostate-specific antigen (PSA) relapse is equivalent to immediate adjuvant radiotherapy (ART) post RP. MATERIAL AND METHODS: 130 patients receiving ART and 89 receiving SRT were identified. All had an undetectable PSA after RP. Homogeneous subgroups were built based on the sta...
32 CitationsSource
#1Thomas WiegelH-Index: 50
#2Dirk BottkeH-Index: 14
Last. Kurt MillerH-Index: 73
view all 20 authors...
Purpose Local failure after radical prostatectomy (RP) is common in patients with cancer extending beyond the capsule. Two randomized trials demonstrated an advantage for adjuvant radiotherapy (RT) compared with a wait-and-see policy. We conducted a randomized, controlled clinical trial to compare RP followed by immediate RT with RP alone for patients with pT3 prostate cancer and an undetectable prostate-specific antigen (PSA) level after RP. Methods After RP, 192 men were randomly assigned to a...
698 CitationsSource
#1Ian M. Thompson (University of Texas Health Science Center at San Antonio)H-Index: 110
#2Catherine M. Tangen (Fred Hutchinson Cancer Research Center)H-Index: 63
Last. E. David Crawford (University of Colorado Hospital)H-Index: 100
view all 12 authors...
Purpose: Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death.Materials and Methods: A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival.Results: Of 425 eligible men 211 were randomized to observation ...
997 CitationsSource
#1Mark Sidhom (Liverpool Hospital)H-Index: 12
#2Andrew Kneebone (Liverpool Hospital)H-Index: 29
Last. Keen Hun Tai (Peter MacCallum Cancer Centre)H-Index: 28
view all 8 authors...
Abstract Background and purpose Three randomised trials have demonstrated the benefit of adjuvant post-prostatectomy radiotherapy (PPRT) for high risk patients. Data also documents the effectiveness of salvage radiotherapy following a biochemical relapse post-prostatectomy. The Radiation Oncology Genito-Urinary Group recognised the need to develop consensus guidelines on to whom, when and how to deliver PPRT. Materials and methods Draft guidelines were developed and refined at a consensus confer...
122 CitationsSource
#1Bruce J. Trock (Johns Hopkins University)H-Index: 86
#2Misop Han (AMA: American Medical Association)H-Index: 61
Last. Patrick C. WalshH-Index: 151
view all 7 authors...
Nearly 60 000 men (27% of newly diagnosed cases) will have undergone radical prostatectomy in 2007.1 Although surgery provides excellent cancer control, approximately 15% to 40% of these men will experience cancer recurrence within 5 years,2,3 usually manifested only by elevated prostate-specific antigen (PSA) level. It is currently difficult to determine whether increasing serum PSA level after surgery represents an isolated recurrence at the surgical site or occult metastases that cannot be de...
534 CitationsSource
#1Carol M. Moinpour (Fred Hutchinson Cancer Research Center)H-Index: 53
#2Katherine A. Hayden (Fred Hutchinson Cancer Research Center)H-Index: 3
Last. E. David Crawford (Fred Hutchinson Cancer Research Center)H-Index: 1
view all 11 authors...
Purpose To compare short- and long-term effects of adjuvant treatment versus observation after surgery on health-related quality of life (HRQL) of prostate cancer patients. Patients and Methods The Southwest Oncology Group (SWOG) intergroup trial compared radical prostatectomy (RP) plus observation versus RP plus adjuvant radiation therapy (RT). Two-hundred seventeen of 425 therapeutic trial patients were eligible and registered to the HRQL study. Patients completed the SWOG Quality of Life Ques...
137 CitationsSource
Cited By91
#1Bernhard Grubmüller (Medical University of Vienna)H-Index: 12
#2Victoria Jahrreiss (Medical University of Vienna)H-Index: 2
Last. Sazan Rasul (Medical University of Vienna)H-Index: 14
view all 11 authors...
Purpose To evaluate the differential impact of postoperative radiotherapy (RT) on recurrence patterns in patients treated with radical prostatectomy (RP) using [68Ga]Ga-PSMAHBED-CC conjugate 11 positron emission tomography (PSMA 11-PET). Methods We assessed 162 consecutive patients who experienced biochemical recurrence (BCR) after RP for nonmetastatic prostate cancer (PC). All had at least one positive lesion on imaging. No patient was on androgen deprivation therapy (ADT). Patients were catego...
#1Alberto Martini (UniSR: Vita-Salute San Raffaele University)H-Index: 27
#2Nicola Fossati (UniSR: Vita-Salute San Raffaele University)H-Index: 36
Last. Alberto Briganti (UniSR: Vita-Salute San Raffaele University)H-Index: 96
view all 25 authors...
Abstract Intermediate clinical endpoints (ICEs) might aid in trial design and potentially expedite study results. However, little is known about the most informative ICE for patients receiving salvage radiation therapy (sRT) after radical prostatectomy. To investigate the most informative ICE for patients receiving sRT, we used a multi-institutional database encompassing patients treated at eight tertiary centers. Overall, 1301 men with node-negative disease who had not received any form of andr...
1 CitationsSource
#1M. Shahait (King Hussein Cancer Center)H-Index: 2
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 12 authors...
1 CitationsSource
#1Robert T. DessH-Index: 16
#2William C. JacksonH-Index: 16
#1Shoji Kimura (Medical University of Vienna)H-Index: 28
#2David D'Andrea (Medical University of Vienna)H-Index: 16
Last. Shahrokh F. ShariatH-Index: 132
view all 17 authors...
Purpose To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa).
2 CitationsSource
#1Cédric Draulans (Katholieke Universiteit Leuven)H-Index: 6
#2Nancy Van DammeH-Index: 3
Last. Karin Haustermans (Katholieke Universiteit Leuven)H-Index: 74
view all 9 authors...
Purpose: The primary aim of the study was to assess the association between having a radiotherapy (RT) department on-site at the surgical centre and the performed postoperative treatment strategy for prostate cancer (PCa) patients. According to the current international guidelines, adjuvant radiotherapy (ART) or a regular prostate-specific antigen (PSA)-based follow-up with (early) salvage radiotherapy ((e)SRT) if needed is recommended in case of adverse pathological characteristics.Material and...
The global COVID-2019 pandemic has presented to the field of radiation oncology a management dilemma in providing evidence-based treatments to all cancer patients There is a need for appropriate measures to be taken to reduce infectious spread between the medical healthcare providers and the patient population Such times warrant resource prioritization and to continue treatment with best available evidence, thereby reducing the risk of COVID-2019 transmission in times where the workforce is redu...
1 CitationsSource
#1Ajalaya Teyateeti (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Bilal Khan (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Yang Lu (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 9 authors...
PURPOSE The aim of the study was to assess the diagnostic performance of fluciclovine positron emission tomography (PET)/computerized tomography (CT) in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen (PSA) ≤0.5 ng/mL, and identify the associated predictive factors of positive studies. PATIENTS AND METHODS From 30 June 2017 to 9 August 2019, patients with post-radical prostatectomy prostate cancer who underwent F-18 fluciclovine PET/CT and had PSA level ...
3 CitationsSource
#1S. Chin (UNSW: University of New South Wales)H-Index: 4
#2Abiola FatimilehinH-Index: 1
Last. Ananya Choudhury (University of Manchester)H-Index: 28
view all 9 authors...
Abstract Purpose Although there is high level evidence supporting moderately hypofractionated radiotherapy for definitive prostate treatment, there is less evidence for its use in the post prostatectomy setting. We externally validated a contemporary nomogram predicting biochemical failure (BF) after salvage radiotherapy (SRT) and report long term disease control outcomes for hypofractionated SRT to the prostate bed. Methods and Materials A retrospective review was performed for 112 patients tre...
12 CitationsSource
#1Akira YokomizoH-Index: 40
#2Masashi WakabayashiH-Index: 11
Last. Jcog InvestigatorsH-Index: 1
view all 19 authors...
Abstract Background No standard therapy has been established for localised prostate cancer patients with prostate-specific antigen (PSA) failure after radical prostatectomy (RP). Objective To determine whether radiotherapy ± hormone therapy is superior to hormone therapy alone in such patients. Design, setting, and participants This study is a multicentre, randomised, open-label, phase 3 trial. Patients with localised prostate cancer whose PSA concentrations had decreased to Outcome measurements...
10 CitationsSource